医学
造血干细胞移植
移植
养生
再生障碍性贫血
内科学
布苏尔班
儿科
免疫学
骨髓
作者
Lan‐Ping Xu,Dao‐Pei Lu,Depei Wu,Erlie Jiang,Dai‐Hong Liu,He Huang,Zimin Sun,Nai-Nong Li,Qifa Liu,Xi Zhang,Yongrong Lai,Yongping Song,Xianmin Song,Sixi Liu,Qian Zhang,Chengjuan Luo,Linghui Xia,Ting Niu,Yu Yu,Xiao‐Hui Zhang,Xiaowen Tang,Yi Luo,Xiao‐Jun Huang
标识
DOI:10.1016/j.jtct.2022.11.011
摘要
Between 2020 and 2021, 31,525 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group throughout mainland China. In this report, we describe the activity and current trends for HSCT in China during the SARS-CoV-2 pandemic. In 2020, a total of 13,415 cases of HSCT were reported from 166 transplantation teams, and 75% (10,042 cases) were allogeneic HSCTs. In 2021, a total of 18,110 cases of HSCT were reported from 174 transplantation teams, and 70% (12,744 cases) were allogeneic HSCTs. Haploidentical donor (HID) transplantation accounted for 63% (7977 cases) of allogeneic HSCTs in 2021. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (37%) and acute lymphoblastic leukemia (23%), and the largest proportion of nonmalignant disease comprised aplastic anemia (13%). The peripheral blood stem cell source accounted for 41% of HIDs and 75% of matched sibling donors. The BuCy-based regimen (57%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu-based regimen (28%) and total body irradiation-based regimen (11%). This survey provides comprehensive information about the current activities and might benefit clinical physicians' decision planning for HSCT.
科研通智能强力驱动
Strongly Powered by AbleSci AI